trial · primary record
Abemaciclib
Recurrent Ovarian High Grade Serous Adenocarcinoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 42 |
| Primary completion | 2026-11-01 |
| Primary endpoint | Recommended phase 2 dose (RP2D) |
| Registry ID | NCT04633239 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:45.669Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04633239
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Abemaciclib · approval
- Abemaciclib · compound